Massively rising COVID-19 cases globally, has urged the companies across medical and pharmaceutical sectors to introduce test kits to potentially detect presence of SARS-CoV-2 virus in an individual. Following this, Florida based Trividia Health has decided to extend its service into COVID-19 care by launching SARS-CoV-2 antibody test kit.
It has been reported that the first phase trial for this test has been acknowledged by the Food and Drug Administration under section IV.D of the organization’s Policy for diagnostic Test for Coronavirus Disease-2019. In fact, the kit is in process of production.
Trividi'a’s SARS-CoV-2 Antibody test Kit is deemed to be a rapid, simple and accurate point of care IgG-IgM merged antibody test kit that can potentially detect IgM and IgG antibodies against the viruses that are responsible for causing COVID-19.
According to official sources, the test offers healthcare experts a fast and convenient way to provide patient results with 15 to 20 minutes. Unlike other detection tests, SARS-CoV-2 test is an effective 2-step operation. The sample volume required for testing is only about 10 microliters of whole blood. The main motive being introduction of this test is to deliver rapid screening which is currently in high demand. Moreover, the test also helps in detection of potential patients and asymptomatic carriers, thereby preventing the secondary transmission and guaranteeing timely treatment measures.
The only constraint associated with the kit is that it is designed for use in various clinical laboratories and healthcare settings excluding its use for at-home testing.
Commenting on the test kit launch, the President and CEO of Trividia Health Scott Verner cited that the company is proud to put forth its novel product across the market that aims at delivering accurate and fast results to patients and healthcare professionals that are searching for testing solutions at a reasonable cost.
He further adds that the company is committed at offering the healthcare experts tools which could quickly and easily test patients and triage the virus on a massive scale. Mr. Verner has shown his firm belief on the test kit stating that it could relieve some stress off the healthcare system a d prepare them for such future COVID-19 virus outbreaks.
As per numerous reports, the second phase of trial would be part of the confirmation process of the ongoing virus with the necessary data being submitted to the regulatory agencies over the time. Moreover, estimates state that the test kits would be made available through major retailers and other distributors and federal government agencies.